Study identifier:D169CR00001
ClinicalTrials.gov identifier:NCT05188144
EudraCT identifier:N/A
CTIS identifier:N/A
Early treatment of heart failure: a non-interventional observational study program of patients with heart failure and initiated on dapagliflozin (EVOLUTION-HF - UK)
heart failure
N/A
No
-
All
237
Observational
n/a - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Feb 2025 by AstraZeneca
AstraZeneca
-
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages. Despite advancements in treatment, a HF diagnosis still leads to significant morbidity and mortality; there is also an immense impact on patients’ health-related quality of life (HRQoL). On May 5, 2020, the US Food and Drug Administration (FDA) announced the approval of dapagliflozin for heart failure with reduced ejection fraction (HFrEF), regardless of whether the patient has diabetes. Subsequently, there have been additional approvals for this indication by regulatory authorities across the globe." Real-world observational data are necessary to describe dapagliflozin use in real-world settings with detailed clinical data on heart failure symptoms, outcomes, and HRQoL
Location
Location
Brighton, Sussex, United Kingdom, BN2 5BE
Location
Stoke-on-Trent, Staffordshire, United Kingdom, AT4 6QG
Location
Port Talbot, Glamorgan, United Kingdom, SA12 7BR
Location
Truro, Cornwall, United Kingdom, TR1 3LJ
Location
Barnstaple, Devon, United Kingdom, EX31 4JB
Location
Westcliff on Sea, Essex, United Kingdom, SS0 0RY
Location
Coventry, Warwickshire, United Kingdom, CV2 2DX
Location
London, Greater London, United Kingdom, SE5 9RS
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.